Citations

Showing 10 of 108081 citations.

Comparison of survival endpoints in glioblastoma patients receiving or not receiving enzyme-inducing anticonvulsants in NCCTG Trials
Jaeckle, Kurt A. , Uhm, Jieun , OʼFallon, Judith R., Schomberg, Paula J., Scheithauer, B. W., Flynn, Patrick J. , Buckner, Jan C. , Ballman, Karla V. , Giannini, Caterina

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 1525-1525

10.1200/jco.2004.22.90140.1525 Get It

Prospective NCCTG quality of life (QOL) study in adult newly diagnosed high-grade gliomas (HGG)
Brown, Paul D. , Rummans, Teresa A. , Sloan, Jeff A. , Arusell, Robert M., Clark, Matthew M. , Buckner, Jan C. , Ballman, Karla V. , Maurer, Matthew J. , Boeve, Bradley F.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 1524-1524

10.1200/jco.2004.22.90140.1524 Get It

Immunohistochemical detection of EGFRvIII and prognostic significance in patients with malignant glioma enrolled in NCCTG clinical trials
Buckner, Jan C. , Aldape, Kenneth, Scheithauer, B. W., Schaefer, Paul, Jenkins, Robert B. , James, C. David , Ballman, Karla V. , Burger, P. C. , Giannini, Caterina

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 1508-1508

10.1200/jco.2004.22.90140.1508 Get It

Phase II study of ZD1839 in patients with newly diagnosed grade 4 astrocytoma
Uhm, Joon H. , Krauss, John C. , Buckner, Jan C. , James, David C. , Scheithauer, B. W., OʼFallon, Judith R., Jaeckle, Kurt A. , Ballman, Karla V. , Giannini, Caterina

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 1505-1505

10.1200/jco.2004.22.90140.1505 Get It

NCCTG phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM)
Buckner, Jan C. , Kreisberg, Jeffrey I., Boni, Joseph , James, C. David , Jenkins, Robert B. , Walsh, Daniel J. , Galanis, Evanthia , Maurer, Matthew J. , Ballman, Karla V. , Hidalgo, Manuel , Walsh, D. J.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 1503-1503

10.1200/jco.2004.22.90140.1503 Get It

An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: Initial report of RTOG 94–02
Cairncross, G., Seiferheld, Wendy, Shaw, Emily , Jenkins, Roger L., Scheithauer, B., Brachman, David, Buckner, Jan C. , Fink, Karen, Souhami, Luís, Curran, Walter J.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 1500-1500

10.1200/jco.2004.22.90140.1500 Get It

Tobacco use among radiation oncology outpatients
Garces, Yolanda I. , Offord, Kenneth P., Croghan, Ivana T. , Decker, Paul A. , Brown, Paul D. , Clark, Matthew M. , Rummans, Teresa A. , Foote, Robert L. , Hurt, R. Douglas , Decker, Paul A.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 1027-1027

10.1200/jco.2004.22.90140.1027 Get It

In re guardianship of Hailu: The Nevada Supreme Court casts doubt on the standard for brain death diagnosis
Yanke, Greg , Rady, Mohamed Y. , Verheijde, Joseph L.

Mayo Clinic

Medicine, Science and the Law | April 5, 2017 | Volume: 57 | Issue: 2 | Pages: 100-102

10.1177/0025802417701036 | PMID 28376670 Get It

In the recent court case of In Re Guardianship of Hailu, the Nevada Supreme Court cast doubt on the acceptability of the American Academy of Neurology’s guidelines as a medical standard for determining brain death. The Uniform Determination of Death Act, which has been adopted in every state, requires that brain death diagnoses be made in accordance with accepted medical standards. The Court expressed concern that the guidelines fail to ensure that there is an irreversible cessation of all functions of a person’s entire brain, which is a component of the Act’s definition of death. Although the Nevada Supreme Court remanded the case to the District Court to hear more expert evidence concerning whether the guidelines constitute “accepted medical standards,” the patient who was the subject of the case met the criteria for cardiopulmonary death several weeks prior to the hearing and the legal case became moot. As a result, the issue of whether the American Academy of Neurology guidelines, or some other criteria for determining brain death, are accepted medical standards for determining whether all brain function has ceased remains unresolved.
Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention
Xie, Jennifer Y. , Felice, Milena De , Kopruszinski, Caroline Machado , Eyde, Nathan, LaVigne, Justin , Remeniuk, Bethany , Yue, Xu , Goshima, Naomi, Ossipov, Michael H. , King, Tamara , Streicher, John M. , Rosen, Hugh , Dodick, David, Hernandez, Pablo, Navratilova, Edita , Dodick, David W. , Roberts, Ed , Porreca, Frank , Kopruszinski, Caroline

Mayo Clinic

Cephalalgia | April 5, 2017 | Volume: 37 | Issue: 8 | Pages: 780-794

10.1177/0333102417702120 | PMID 28376659 Get It

Background Stress is the most commonly reported migraine trigger. Dynorphin, an endogenous opioid peptide acting preferentially at kappa opioid receptors (KORs), is a key mediator of stress responses. The aim of this study was to use an injury-free rat model of functional cephalic pain with features of migraine and medication overuse headache (MOH) to test the possible preventive benefit of KOR blockade on stress-induced cephalic pain. Methods Following sumatriptan priming to model MOH, rats were hyper-responsive to environmental stress, demonstrating delayed cephalic and extracephalic allodynia and increased levels of CGRP in the jugular blood, consistent with commonly observed clinical outcomes during migraine. Nor-binaltorphimine (nor-BNI), a long-acting KOR antagonist or CYM51317, a novel short-acting KOR antagonist, were given systemically either during sumatriptan priming or immediately before environmental stress challenge. The effects of KOR blockade in the amygdala on stress-induced allodynia was determined by administration of nor-BNI into the right or left central nucleus of the amygdala (CeA). Results KOR blockade prevented both stress-induced allodynia and increased plasma CGRP. Stress increased dynorphin content and phosphorylated KOR in both the left and right CeA in sumatriptan-primed rats. However, KOR blockade only in the right CeA prevented stress-induced cephalic allodynia as well as extracephalic allodynia, measured in either the right or left hindpaws. U69,593, a KOR agonist, given into the right, but not the left, CeA, produced allodynia selectively in sumatriptan-primed rats. Both stress and U69,593-induced allodynia were prevented by right CeA U0126, a mitogen-activated protein kinase inhibitor, presumably acting downstream of KOR. Conclusions Our data reveal a novel lateralized KOR circuit that mediated stress-induced cutaneous allodynia and increased plasma CGRP in an injury-free model of functional cephalic pain with features of migraine and medication overuse headache. Selective, small molecule, orally available, and reversible KOR antagonists are currently in development and may represent a novel class of preventive therapeutics for migraine.
Correlation of Symptoms, Clinical Signs, and Biomarkers of Inflammation in Postsurgical Chronic Rhinosinusitis
Racette, Samuel D. , Wijewickrama, Rohan C., Jayaprakash, Vijayvel , Sherris, David A., Kita, Hirohito , O’Donnell, Frank E., Ponikau, Jens U., Santos, Carlos Henrique Marques dos , Kita, H

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | April 5, 2017 | Volume: 126 | Issue: 6 | Pages: 455-462

10.1177/0003489417701939 | PMID 28376637 Get It

Objective: The study aimed to evaluate symptoms described by patients with chronic rhinosinusitis with polypoid changes/nasal polyps and their correlation with computed tomography (CT), nasal endoscopy, and intranasal biomarkers. Study Design: Prospective multicenter study symptom data from postsurgical adult chronic rhinosinusitis study participants with recurrent disease refractory to medical therapy were analyzed in comparison with objective data. Methods: Using logistic regression analysis, participant-rated 16-question surveys from 258 participants were assessed for correlation with nasal endoscopy scores, CT percentage of sinus occlusion, and intranasal biomarkers of fungal antigens (Alternaria and Aspergillus), eosinophilic inflammation (eosinophil-derived neurotoxin [EDN] and major basic protein [MBP]), and inflammatory cytokines (interleukins 5 and 13). Results: Study participant assessments revealed increased CT occlusion in participants presenting with greater inability to smell ( P < .019). Mucosal inflammation identified on nasal endoscopy was positively correlated with congestion ( P < .028), runny nose ( P < .002), and ear pain ( P < .007). Elevated EDN was positively correlated in patients with bothersome congestion ( P < .031) and runny nose ( P < .011). Sneezing was positively correlated with multiple markers: Alternaria ( P < .024), interleukin-13 ( P < .027), MBP ( P < .034), and interleukin-5 ( P < .019). Conclusion: Nasal endoscopy, not CT imaging, has the strongest correlation with the 2 cardinal symptoms of congestion and runny nose in CRS patients; these correlate with biomarkers of eosinophilic inflammation.